Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

NCT06771115 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of an experimental drug called VTX3232, taken alone or with semaglutide, in adults with obesity.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 176 people

Who can join Ages 18–80 · all sexes

Timeline Started 2025-01 · est. completion 2025-09

Where 14 sites · United States

What this study is testing ClinicalTrials.gov NCT06771115 ↗

Description as written by the study sponsor.

This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide. This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.

Treatments tested

VTX3232 Dose A Drug

VTX3232 Dose A
Placebo Drug

Placebo
VTX3232 Dose A in combination with semaglutide Drug

VTX3232 Dose A in combination with semaglutide
Placebo in combination with semaglutide Drug

Placebo in combination with semaglutide

Main thing measured	Incidence Rate and Severity of Adverse Event (AE), Serious Adverse Event (SAE), and AEs leading to study treatment discontinuation through study completion
Sponsor	Zomagen Biosciences Ltd.
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06771115 ↗